

EUROPEAN SOCIETY OF INTENSIVE CARE MEDICINE COVID-19 Project (UNITE-COVID)

PATIENT CRF Version 19MAY20



CLINICAL INCLUSION CRITERIA (all required)					
Proven infection with SARS-CoV2 ☐ Yes ☐ No Critically ill with COVID-19 ☐ Yes ☐ No					
DEMOGRAPHICS					
Sex □ Male □ Female □ Not specified Age [][] years Height [][] cm Weight [][] kg Healthcare Worker? □ Yes □ No □ Unknown Pregnant? □ Yes □ No □ Unknown □ N/A					
Episode information					
LOS in ICU prior to May 4th [][][] days LOS in hospital prior to May 4th [][][] days Interval start of symptoms - May 4th [][][] days Interval start of symptoms - May 4th [][][] days Interval start of symptoms - May 4th [][][] days Interval start of symptoms - May 4th [][][] days Interval start of symptoms - May 4th [][][][] days Interval start of symptoms - May 4th [][][][][][][][][][][][][]					
COMORBIDITIES (existing prior to admission)					
Chronic cardiac disease (not hypertension)	☐ Yes ☐ No ☐ Unknown	Chronic liver disease	☐ Yes ☐ No ☐ Unknown		
- 31	☐ Yes ☐ No ☐ Unknown	Chronic neurological disorder	☐ Yes ☐ No ☐ Unknown		
Chronic pulmonary disease	☐ Yes ☐ No ☐ Unknown	Diabetes	☐ Yes ☐ No ☐ Unknown		
, ,	☐ Yes ☐ No ☐ Unknown	Malignant neoplasm	☐ Yes ☐ No ☐ Unknown		
	☐ Yes ☐ No ☐ Unknown	Immunosuppression	☐ Yes ☐ No ☐ Unknown		
HIV ☐ Yes-on ART ☐ Yes-no					
	PRE-ADMISSION & CHRONIC MEDICATION Did the patient receive any of these regularly in 14 days prior to admission?				
ACE inhibitors	☐ Yes ☐ No ☐ Unknown	Anticoagulation	☐ Yes ☐ No ☐ Unknown		
Angiotensin II receptor blockers	☐ Yes ☐ No ☐ Unknown	Antiplatelet therapy	☐ Yes ☐ No ☐ Unknown		
ICU Admission data	2 res 2 re 2 crimient	7 translateret trierasy	a res a re a crimioni		
ICU Admission diagnosis ☐ Respira	atory failure due to COVID-19. F	Other complication of COVID-19	□ Other diagnosis		
		Other complication of COVID-13	Utilei diagnosis		
If other than Respiratory failure, pla		F. D. D. C. Other D. Name days are	t - d		
Was a thromboembolic complication	•		rted		
Did the patient receive respiratory					
If YES, which type of support? ☐ S					
Total duration of support (HFNO, C		<u>=</u>			
Clinical and lab parameters on adm					
Highest Temperature (°C) [][Highest neutrophil count (109/ml of		Highest total white cell count (Lowest Lymphocyte count			
Highest C-reactive protein (mg/L)			lcitonin (ng/mL) [][],[]		
Highest ferritin (mg/L) [][][][• ,	oponinT (ng/mL) [][],[]		
		3)poniiri (iig/iiiL) [],[]		
Clotting parameters on admission (Highest fibrinogen (g/L) [][(record nignest/lowest value in 24],[] Highest aPTT (sec) [o-dimers (ng/mL) [][]		
Lowest platelet count (10 ³ /ml of bl			ombin time (sec) [][]		
COMPLICATIONS: At any time during					
Cardiac arrhythmia req therapy	☐ Yes ☐ No ☐ Unknown	Prolonged delirium	☐ Yes ☐ No ☐ Unknown		
Sepsis induced myocardiopathy	☐ Yes ☐ No ☐ Unknown	Seizure	☐ Yes ☐ No ☐ Unknown		
Stress myocardiopathy	☐ Yes ☐ No ☐ Unknown	Pressure sores – facial (prone)	☐ Yes ☐ No ☐ Unknown		
Myocarditis	☐ Yes ☐ No ☐ Unknown	Pressure sores – other	☐ Yes ☐ No ☐ Unknown		
Pericardial effusion	☐ Yes ☐ No ☐ Unknown	Acute kidney injury	☐ Yes ☐ No ☐ Unknown		
Pneumothorax	☐ Yes ☐ No ☐ Unknown	Tube obstruction	☐ Yes ☐ No ☐ Unknown		
Atelectasis	☐ Yes ☐ No ☐ Unknown	Accidental extubation	☐ Yes ☐ No ☐ Unknown		
MEDICATION: While hospitalized in	the ICU were any of the following	ng administered?			
Antivirals? □Yes □No □Unknown			or □ Remdesivir		
Other: □Interferon alpha □Interf		·			
Corticosteroid? □Yes □No □Unkr	nown If yes, total duration: [][]days and interval after admiss	ion [][] days		
If yes, indication: ☐ Shock ☐ Hype	rinflammation \square Pneumonitis \square	Pre-existing condition \square Other			
Antimalarial agent? □Chloroquine □Hydroxychloroquin □None If yes, total duration: [][] days Was the patient included in a clinical trial (drug) □Yes □No □Unknown					
SUPPORTIVE CARE: During hospitalization, did the patient receive/undergo:					
Sedation? ☐ Yes ☐ No ☐ Unknown If yes, total duration: [][] days Renal replacement therapy (RRT) or dialysis? ☐ Yes ☐ No ☐ Unknown If yes, total duration: [][] days					
If yes, method: □ CRRT □ Intermittent □ Peritoneal dialysis □ Mixture RRT method outside unit's usual practice? □Yes □No Other form of extracorporeal blood purification? □ Yes □ No If yes: □ hemoperfusion □ hemoadsorption □ other					
Inotropes/vasopressors? Yes No Unknown If yes, total duration:					
Was the patient tracheostomized? □Yes □No □Unknown If yes, at which day of mechanical ventilation [1]					



EUROPEAN SOCIETY OF INTENSIVE CARE MEDICINE COVID-19 Project (UNITE-COVID-19) _ CRF

If yes: □Surgical □Dilatative/percutaneous □Unknown						
Clinical and lab parameters during ICU stay (record highest/lowest value DURING ICU admission)						
Highest Temperature (°C) [][],[] Highest total white cell count (109/ml of blood) [][][]						
,			nt (10 ⁹ /ml of blood[][][]			
Highest ferritin (mg/L) [][roponinT (ng/mL) [][],[]			
OUTCOME – to be evaluated at 60 days after admission to the ICU (based on information in ICU and hospital records)						
Outcome: □Still in ICU □Hospitalized □Transfer to other facility □Discharged alive □Death □Palliative discharge □Unknown						
If no longer in ICU, ICU admission duration: [][] days						
If discharged alive/transfer, hospital admission duration: [][] days If discharged alive, was patient still on RRT? □Yes □No						
DOMAIN Respiratory						
Was the patient intubated at ICU admission? □Yes □No If not, was the patient intubated during the ICU stay? □Yes □No						
If the patient was intubated during the ICU stay, how many days after admission [][] days						
During ICU stay, did the patient receive any of the following:						
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □Unknown HFNC? □Yes □No □Unknown						
If yes, total duration before intubation: [][] days If yes, total duration after intubation: [][] days						
Invasive ventilation (Any) Yes No Unknown If yes, total duration: [] days						
-	? □Yes □No □Unknown If yes, t	•				
		ed: [][] days If yes, duration	not intubated: [][] days			
•	□No □Unknown If yes, total c	•	not masated. []			
	•	□ Standard oxygen □HFNO □CPAP	! □NIV			
	dicate the ventilatory settings on					
i i	•	L)	<i>r 1r 1</i>			
		Hg): [][] Driving Press				
		s the weaning process?: □Normal [□Difficult □Prolonged			
Was the patient reintubated after initial extubation? □Yes □No □Unknown						
DOMAIN Coagulation	have free and high art flavoration by	OLIDING IGH advisarion)				
DOMAIN Coagulation Clotting parameters during ICU st			11 11 1			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[] High	DURING ICU admission) est D-dimers (10 ⁹ /ml of blood) [t platelet count (10 ⁹ /ml of blood) [
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [],[],[] Lowest platelet count (109/ml of	High blood) [][] Highes	est D-dimers (10 9 /ml of blood) [
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec)	High- blood) [][] Highes [][] Highest aPTT (n	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [ng/L) [][] Highest ferrit				
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h	Highblood) [][] Highes Highes Highes aPTT (mof admission: drug and daily dos	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [ng/L) [][] Highest ferrit				
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi	High- blood) [][] Highes [][] Highest aPTT (n of admission: drug and daily dos rst 24h of drug, daily dose)	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [ng/L) [][] Highest ferrit e)][] in (mg/L) [][]			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con	High- blood) [][] Highes [][] Highest aPTT (m of admission: drug and daily dos rst 24h of drug, daily dose) nplications (e.g. shock, airway co	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [_ ng/L) [][] Highest ferrit e) mpromise, intracranial mass effect,][][] in (mg/L) [][] etc.): □Yes □No			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □	High- blood) [][] Highes [][] Highest aPTT (m of admission: drug and daily dos rst 24h of drug, daily dose) nplications (e.g. shock, airway co Respiratory tract □CNS □Other	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [_ng/L) [] Highest ferrite) mpromise, intracranial mass effect, Number of Packed cells transfus][][] in (mg/L) [][] etc.): □Yes □No			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □Gl □ Thromboembolic complications □	High- blood) [] [] Highes [][] Highest aPTT (n of admission: drug and daily dos rst 24h of drug, daily dose) nplications (e.g. shock, airway co Respiratory tract □CNS □Other □DVT □PE □Myocardial infarction	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [_ng/L) [][] Highest ferritele) mpromise, intracranial mass effect, Number of Packed cells transfuson □Limb ischemia □ Stroke][] in (mg/L) [][] etc.): □Yes □No ed : [][]			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye	Highblood) [] Highess aPTT (mof admission: drug and daily dose) arst 24h of drug, daily dose) applications (e.g. shock, airway colarespiratory tract \(\to \text{CNS} \) \(\	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [st platelet count (109/ml of blood) [] eg/L) [][] Highest ferrit e) mpromise, intracranial mass effect, Number of Packed cells transfus on □Limb ischemia □ Stroke H □ other; interval after ICU admi][][] in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [][]			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye	Highblood) [] Highess aPTT (mof admission: drug and daily dose) arst 24h of drug, daily dose) applications (e.g. shock, airway colarespiratory tract \(\to \text{CNS} \) \(\	est D-dimers (10 ⁹ /ml of blood) [st platelet count (10 ⁹ /ml of blood) [_ng/L) [][] Highest ferritele) mpromise, intracranial mass effect, Number of Packed cells transfuson □Limb ischemia □ Stroke][][] in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [][]			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □Gl □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ D DOMAIN Infection	Highblood) [] Highess aPTT (mof admission: drug and daily dose) arst 24h of drug, daily dose) applications (e.g. shock, airway colarespiratory tract \(\to \text{CNS} \) \(\	est D-dimers (109/ml of blood) [st platelet count (109][][] in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [][]			
Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □G □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ D DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk	High- blood) [] [] Highes [] [] Highest aPTT (nr of admission: drug and daily dose rst 24h of drug, daily dose) nplications (e.g. shock, airway co Respiratory tract □CNS □Other □DVT □PE □Myocardial infarction DVT □PE □Myocardial infarction wing within 24 hours of ICU admissions if yes insert codes here [_	est D-dimers (109/ml of blood) [st platelet count][][] in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [][]			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [], [], [] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ D DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk	Highes blood) [] [] Highes aPTT (m of admission: drug and daily dos rst 24h of drug, daily dose) nplications (e.g. shock, airway coll Respiratory tract CNS Other DDVT PE Myocardial infarction No ; if yes UFH LMW DVT PE Myocardial infarction wing within 24 hours of ICU admissions if yes insert codes here Lanown if yes	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [st platelet count (109/ml of blood) [st platelet count (109/ml of blood) [] mg/L) [][] Highest ferrite e) mpromise, intracranial mass effect, Number of Packed cells transfus on □Limb ischemia □ Stroke H □ other; interval after ICU admi □limb ischemia □Line or filter clot ission? [] - [][] - [][] -][][] in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [][]			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infe	High- blood) [] [] Highest blood) [] [] Highest aPTT (mof admission: drug and daily dose) rst 24h of drug, daily dose) nplications (e.g. shock, airway collaborations) Respiratory tract CNS Other DVT PE Myocardial infarction	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [st platelet cou	in (mg/L) [] [] etc.): etc.): etc.): etc.): etc.): output e			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection	Highblood) [][] Highest aPTT (mof admission: drug and daily dosents 24h of drug, daily dosents 24h of daily dosents 24h of daily dosents 24h of daily dosents 24h of daily	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [_ng/L) [][] Highest ferrite) mpromise, intracranial mass effect, Number of Packed cells transfus on □Limb ischemia □ Stroke H □ other; interval after ICU admi □limb ischemia □Line or filter clot ission? □[_] - [_][_] - [_][_] - [_] - [_] es □ No □ Yes □ No If yes, severity □ Se	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □Prophylaxis □Previous condition □[_] □[_] □J[] epsis □ Septic shock			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infe	High- blood) [] [] Highest blood) [] [] Highest aPTT (mof admission: drug and daily dose) rst 24h of drug, daily dose) nplications (e.g. shock, airway collaborations) Respiratory tract CNS Other DVT PE Myocardial infarction	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [st platelet cou	in (mg/L) [] [] etc.): etc.): etc.): etc.): etc.): output e			
DOMAIN Coagulation Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Bacterial pulmonary infection	Highblood) [] Highest aPTT (mof admission: drug and daily dose) Inplications (e.g. shock, airway complications) Respiratory tract CNS Other DVT PE Myocardial infarctions In Myocardial infarctions	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [_ng/L) [][] Highest ferrite) mpromise, intracranial mass effect, Number of Packed cells transfuson	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □Prophylaxis □Previous condition [][] [][] epsis □ Septic shock □ Yes □ No			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Pe Indication for anticoagulation □ Pe Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection Bacterial pulmonary infection Abdominal infection Bacteremia (not catheter related)	High-blood) [] Highest aPTT (nr of admission: drug and daily dose rst 24h of drug, daily dose) Inplications (e.g. shock, airway coal Respiratory tract CNS Other DVT PE Myocardial infarction Wing within 24 hours of ICU admission if yes insert codes here Lection present at admission? Yestion at any point during ICU stay Yestion No Yestion Y	est D-dimers (109/ml of blood) [st platelet count []	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □ □Prophylaxis □Previous condition □ [] □ [] □ [] □			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Pe Indication for anticoagulation □ Pe Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection Bacterial pulmonary infection Abdominal infection Bacteremia (not catheter related) Was an MDR pathogen involved	High-blood) [] Highest aPTT (mof admission: drug and daily doserst 24h of drug, daily dose) Inplications (e.g. shock, airway collaborations) Respiratory tract CNS Other DVT PE Myocardial infarction OVT	est D-dimers (109/ml of blood) [st platelet count []	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □ □Prophylaxis □Previous condition □ [] □ [] □ [] □			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Ye Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection Endet of the patient of the patient develop and infection Bacteremia (not catheter related) Was an MDR pathogen involved Days alive without anti-microbia	High-blood) [] Highest aPTT (mof admission: drug and daily doserst 24h of drug, daily dose) Inplications (e.g. shock, airway collaborations) Respiratory tract CNS Other DVT PE Myocardial infarction OVT	est D-dimers (109/ml of blood) [st platelet count []	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □ □Prophylaxis □Previous condition □ [] □ [] □ [] □			
Clotting parameters during ICU st Lowest fibrinogen () [][],[_ Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □G □ Thromboembolic complications □ Therapeutic anticoagulation □ Pe Indication for anticoagulation □ Pe Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antifungal □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Bacterial pulmonary infection Fungal respiratory infection Bacteremia (not catheter related) Was an MDR pathogen involved Days alive without anti-microbia DOMAIN Rehabilitation	High- blood) [Highes blood) [Highes close Highest aPTT (nor fadmission: drug and daily dose) const 24h of drug, daily dose) const 24h of daily dose) const	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [_ng/L) [][] Highest ferrite. e) mpromise, intracranial mass effect, Number of Packed cells transfus on □Limb ischemia □ Stroke H □ other; interval after ICU admi □limb ischemia □Line or filter clot ission? □[_] - [_] [_] - [_] [_] - es □ No □ Yes □ No If yes, severity □ Se Urinary tract infection CNS infection Other infection CLABSI MRSA □ VRE □ MDR-PA □ CRE □	in (mg/L) [][] etc.):			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Pe Indication for anticoagulation □ Pe Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection Bacterial pulmonary infection Fungal respiratory infection Bacteremia (not catheter related) Was an MDR pathogen involved Days alive without anti-microbia DOMAIN Rehabilitation Was the patient mobilized in the	Highes blood) [] [] Highes aPTT (mof admission: drug and daily dose) and	est D-dimers (109/ml of blood) [_st platelet count (109/ml of blood) [_ng/L) [] [] Highest ferrite. e) mpromise, intracranial mass effect, Number of Packed cells transfus on Limb ischemia Stroke H other; interval after ICU admi limb ischemia Line or filter clot ssion? - - - ses No fyes, severity Severity	in (mg/L) [][] etc.): □Yes □No ed: [][] ssion [] □ □Prophylaxis □Previous condition □ [] □ [] □ [] □			
Clotting parameters during ICU st Lowest fibrinogen () [][],[] Lowest platelet count (109/ml of Highest prothrombin (time (sec) DVT prophylaxis (during first 24h Antiplatelet prophylaxis (during fi Life-threatening hemorrhagic con Source of bleeding □Lines □GI □ Thromboembolic complications □ Therapeutic anticoagulation □ Pe Indication for anticoagulation □ Pe Indication for anticoagulation □ DOMAIN Infection Did the patient receive the follow Antibiotics □ Yes □ No □ Unk Antifungal □ Yes □ No □ Unk Was bacterial pulmonary co-infection Did the patient develop an infection Bacterial pulmonary infection Fungal respiratory infection Bacteremia (not catheter related) Was an MDR pathogen involved Days alive without anti-microbia DOMAIN Rehabilitation Was the patient mobilized in the	High- blood) [Highes blood) [Highes close Highest aPTT (nor fadmission: drug and daily dose) const 24h of drug, daily dose) const 24h of daily dose) const	est D-dimers (109/ml of blood) [st platelet count (109/ml of blood) [_ng/L) [] [] Highest ferrite. e) mpromise, intracranial mass effect, Number of Packed cells transfus on □Limb ischemia □ Stroke H □ other; interval after ICU admi □limb ischemia □Line or filter clot ission? □[_] - [_] [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [_] - [] - [in (mg/L) [][] etc.): □Yes □No ed: [][] Ssion [][] □Prophylaxis □Previous condition □ [] □ Epsis □ Septic shock □ Yes □ No ESBL □ Acinetobacter			



Information for completing the UNITE COVID19 patient CRF